《新股表現》健世科技(09877.HK)開報28元 高上市價0.7%
健世科技-B(09877.HK)上周五暗盤高低見29元/26.95元,收28元,高上市價0.7%;該股今日首掛開報28元,較上市價27.8元,高0.7%,市前成交8.2萬股。
健世是內地寧波醫療器械公司,致力於開發用作治療結構性心臟病的介入產品。健世是次來港上市合共發售807.64萬股,並已引入先健科技(01302.HK)為基石投資者認購564.66萬股;其中10%公開發售獲0.52倍超購,認購一手中籤率58%;股份以接近招股範圍(26.7-28.8元)中間位定價,料集資淨額約1.55億元,主要用作核心產品(即LuX-Valve與KenValve)研發、製造和商業化,以及用於產品管線其他在研產品(包括LuX-Valve Plus、KenFlex和二尖瓣產品)研發、臨床試驗及產品註冊等。上市聯席保薦人分別為中金及花旗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.